Charlie Firth

Mr. Charlie Firth

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2024 in Education Sciences
Verified
Journal Article
Open access
PDF file
SYSarah Younie
Sarah Younie
SCSapphire Crosby
Sapphire Crosby
CFCharlie Firth
Charlie Firth
JMJohanna McNicholl
Johanna McNicholl
KLKatie Laird
Katie Laird
Becoming one of the first studies in the field to do so, specially developed educational interventions (Germ’s Journey), designed to teach children about respiratory tract infection prevention, were delivered to 273 pupils aged five to six across five primary schools in the U.K. The intervention aimed to increase understanding of pathogens and respiratory tract illness, transmission and infection prevention, and preparedness for future pandemics due to a lack of such resources for young children at present. To assess the impact of the intervention, children were asked five questions related to knowledge of pathogens, transmission of infection, and infection prevention directly before and after activity-based workshops, as well as one month later. Responses were scored for pupils’ level of knowledge; differences in the frequency of responses between the time points were analysed using Pearson’s chi-squared test. Teachers also took part in semi-structured interviews to evaluate the workshop from the educators’ points of view. Children showed increased knowledge in all three areas immediately after the workshops. This improvement was retained to a lesser or equal extent one month following the learning intervention workshop. The consistent use of teaching resources and interventions such as Germ’s Journey should be implemented in the school curriculum in order to increase understanding and reduce the transmission of respiratory tract illness. Specially designed activity-based workshops using a range of learning skills can help young children to understand the link between pathogens, and infection transmission and control.

4 June 2026 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
CFCharlie Firth
Charlie Firth
NDNeha Kumari Das
Neha Kumari Das
EKErina Khatri
Erina Khatri
SBSanjeev Bijukchhe
Sanjeev Bijukchhe
SCSachi Chuke
Sachi Chuke
BABipin Adhikari
Bipin Adhikari
Pediatric vaccine trials are essential for generating evidence to inform immunization policy, yet their success depends on effective recruitment and sustained participation of children and their caregivers. Understanding parental decision-making is particularly important in low- and middle-income countries, where sociocultural dynamics, trust, and access to healthcare may shape willingness to participate in research. This qualitative study explored parental motivations, facilitators, and barriers to participation in a pediatric vaccine clinical trial conducted in Kathmandu Valley, Nepal. Semi-structured interviews were conducted with 33 parents whose children were enrolled in the OptImms trial, a randomized study evaluating alternative diphtheria, tetanus, and pertussis (DTwP) immunization schedules. Interviews were conducted in Nepali, transcribed, translated, and analyzed thematically. Trust in healthcare workers, research institutions, and scientific processes emerged as a central facilitator of participation. Social dynamics, including joint decision-making within families and reassurance from relatives working in healthcare, strongly influenced enrollment decisions. Practical facilitators, such as efficient scheduling, access to additional healthcare, and reimbursement for travel costs, further supported participation. Barriers included time constraints, geographical distance, and concerns about invasive procedures, such as blood sampling. These findings highlight the importance of trust-building, culturally sensitive communication, and logistical support in the ethical design and implementation of pediatric vaccine trials. Addressing these factors may improve recruitment and retention in future vaccine trials in Nepal and similar settings.

1 January 2026 in BMJ Public Health
Verified
Journal Article
Open access
CFCharlie Firth
Charlie Firth
SWSophia Wilkinson
Sophia Wilkinson
SMSam Martin
Sam Martin
SVSamantha Vanderslott
Samantha Vanderslott
APAndrew J Pollard
Andrew J Pollard
KPKatrina M Pollock
Katrina M Pollock
Introduction: Antimicrobial-resistant gonorrhoea poses a significant global public health threat. In response, the UK launched the world’s first gonorrhoea vaccination programme using a 4CMenB vaccine, targeting individuals at high risk of bacterial sexually transmitted infections (STIs). Understanding attitudes and acceptability among sexual health service users is essential to inform successful implementation. Methods: The NAVIGATE study employed a mixed-methods design, combining an online survey (n=395) with semi-structured interviews (n=15) among UK adults who had previously accessed sexual health services. The survey included demographic questions, the validated Vaccination Attitudes Examination scale and items assessing the acceptability of gonorrhoea vaccine. Interviews explored deeper perceptions of vaccination, trust and delivery preferences. Quantitative data were analysed descriptively and qualitative data thematically using Braun and Clarke’s framework. Results: Participants showed high general vaccine confidence, with 92.2% strongly supporting a gonorrhoea vaccine programme. Acceptance was driven by concerns about antimicrobial resistance and trust in UK regulatory systems. Stigma and structural barriers, such as fear of judgement, cost and inconvenient delivery settings, were key factors influencing access. Participants favoured delivery through sexual health clinics and LGBTQ+ venues and strongly endorsed peer-led outreach. Partial efficacy of the proposed vaccine was accepted when transparently communicated. Concerns over personal costs emerged as potentially worsening inequalities. Conclusions: While overall acceptability was high, successful uptake requires delivery that is trusted, stigma-free, accessible and clearly communicated. Policy recommendations include ensuring free access, leveraging peer-led campaigns and delivering vaccination in low-barrier settings. Monitoring by demographic group is essential to prevent inequities. These insights are crucial as the UK’s pioneering programme generates global evidence for future STI vaccine policy.